SGMT
No price yet
Announcements
Nothing here yet
Daily updates
- Sagimet Biosciences reported 52-week Phase 3 open-label extension results for partner Ascletis’ denifanstat in acne, showing a 57% IGA success rate, a 72% reduction in total lesions, and a 77% reduction in inflammatory lesions, with favorable tolerability.Oct 10, 2026
- Sagimet reported favorable 52-week Phase 3 open-label extension results from partner Ascletis for denifanstat in Chinese acne patients, with a 56.7% IGA success rate and substantial reductions in total and inflammatory lesions.Sep 30, 2026
- Sagimet Biosciences scheduled a September 30 presentation of 52-week open-label Phase 3 extension results for denifanstat in moderate-to-severe acne, with prior China data showing sustained efficacy beyond Week 12.Sep 29, 2026
FDA designations
Nothing here yet
News
- Sagimet will present positive 52-week results from Ascletis' Phase 3 open-label extension study of denifanstat for acne, along with mechanistic data, at the 2026 Fall Clinical Dermatology ConferenceOct 9, 2026
- Sagimet reports positive full 52-week results from Ascletis' Phase 3 open-label extension study of denifanstat in acne, presented at EADV 2026Sep 30, 2026
- Sagimet Biosciences received FDA clearance and a Study May Proceed letter for its Phase 3 acne trial in adolescents and adultsAug 13, 2026
- Sagimet Biosciences to present mechanism of action data for FASN inhibitors at dermatology conferenceMay 11, 2026
- Sagimet Biosciences announced pricing of a $175 million underwritten offering of Series A common stockApr 27, 2026